The purpose of this study is in a phase I/II safety and efficacy study to evaluate the clinical effect of coronary artery bypass graft (CABG) combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty for patients with ischemic cardiomyopathy.
Who can participate
Age range20 Years ā 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female;
* 20-70 years old;
* Ability to give informed consent;
* Documented severe coronary heart disease, defined as at least 70% luminal diameter narrowing of at least three major coronary artery, suited to CABG;
* Left ventricular dysfunction (LVEF) less than or equal to 35%, measured by MRI or less than or equal to 45%, measured by echocardiogram;
* Presence of reversibility, as identified by single photon emission computed tomography (SPECT) isotope protocol;
* At least 3 months since last episode of myocardial infarction;
* Without a history of abdominal operation and severe abdominal diseases;
* Negative pregnancy test (in women with childbearing potential.
Exclusion Criteria:
* Pregnant or lactating;
* A history of malignancy in the last 5 years excluding basal cell carcinoma, that has been surgically removed, with proof of surgical clean margins;
* a history of abdominal operation or severe abdominal diseases;
* Positive test result for human immunodeficiency virus (HIV), hepatitis B, or hepatitis C
* Any condition requiring immunosuppressive medication;
* Bleeding diathesis, defined as an international normalized ratio of at least 2.0 in the absence of warfarin therapy;
* Hepatic dysfunction, as defined as aspartate aminotransferase (AST) or alanine aminotransferase (ALT) more than 1.5 times the upper limit of normal range prior to study entry;
* Chronic renal insufficiency, defined as a serum creatinine level greater than 2.5 mg/dL ā¦